An interesting report on the Ivanhoe Newswire reports that patients at the University of Rochester Center in New York who have taken Clozapine have drastically greater rates of metabolic syndrome, which increases their chance of getting diabetes, stroke and heart diseases. Clozapine is the only product that the Food and Drug Administration approves for treatment of suicidal behavior.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.